Long COVID Clinical Trial
Official title:
A Randomized Controlled Trial of Smell Training and Trigeminal Nerve Stimulation in the Treatment of COVID-related Persistent Smell Loss
Persistent smell loss that can include diminished or distorted smell function is a common symptom of long COVID syndrome. There are limited treatment options for long COVID-related smell loss. This study aims to determine the efficacy of two at-home treatments, smell training and non-invasive trigeminal nerve stimulation. This study requires participants to conduct daily at-home treatment sessions, attend three in-person study visits at the MUSC Department of Psychiatry and Behavioral Sciences, and complete electronic questionnaires over the 12-week trial, and again at the six-month timepoint. Participants in this trial may benefit directly with an improvement in sense of smell. However, participation may also help society more generally, as this study will provide new information about long COVID-related smell loss and its treatment.
Status | Recruiting |
Enrollment | 180 |
Est. completion date | May 31, 2028 |
Est. primary completion date | May 31, 2028 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - treatment-seeking for COVID-related persistent SL (anosmia, hyposmia, phantosmia or parosmia) - SARS-coV-2 PCR-positive test prior to April 2021 - normal sense of smell prior to COVID - naïve to both smell training (ST) and trigeminal nerve stimulation (TNS) - able to comprehend English and provide informed consent Exclusion Criteria: - history of head injury (e.g. sport, accident, combat blast) - sinonasal condition (e.g. upper respiratory infection, rhinosinusitis, polyps) - neurological disorder (e.g. epilepsy, neurodegenerative disorder, narcolepsy) - serious mental illness (e.g. schizophrenia, bipolar, or other psychotic disorder) - suicidal ideation within the last month - current (=6 months) heavy cigarette smoker (heavy defined as = 10 pack-years) - oral/nasal steroids or other intranasal medications within the last month - immunomodulatory medications - pregnant or trying to become pregnant |
Country | Name | City | State |
---|---|---|---|
United States | Medical University of South Carolina | Charleston | South Carolina |
Lead Sponsor | Collaborator |
---|---|
Medical University of South Carolina | National Institute on Deafness and Other Communication Disorders (NIDCD), National Institutes of Health (NIH) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Treatment Feasibility, Acceptability, and Fidelity at 4 and 12 weeks | Quantitative measurements will include the number of 1) sessions completed (completion rate), 2) technical problems, 3) adverse events, 4) study drop-out, and 5) the number of study-issued treatment cases returned at the end of treatment. The Feasibility of Intervention Measure (FIM) and the Acceptability of Intervention Measure (AIM) will be used. Both the FIM and AIM contain 4 items that are scored on a 5-point scale (1=completely disagree to 5=completely agree). Responses are averaged across the 4 items, with a score of 4 or more indicating adequate feasibility and acceptability of an intervention. Fidelity (i.e. adherence) that the treatment is delivered as intended will be measured by study staff who will rate adherence on a 5-point scale (1=little to 5=complete). Qualitative data using open-ended questions regarding the nature of any technical problems and the reasons for missed treatment sessions will be assessed. | 2 times: 4 weeks, 12 weeks | |
Other | Durability of Treatment on Subjective Olfactory Function at the 6-month Follow Up | Subjective function will be assessed with the QOD-NS and IOL-VAS. | 1 time: 6 months | |
Other | Durability of Treatment on Long COVID Symptoms at the 6-month Follow Up | 53 long COVID symptoms (scored from 0-53 reflecting the number of different symptoms experienced) and the impact of those symptoms (scored from 0=no impact to 10=maximal impact) will be obtained. | 1 time: 6 months | |
Other | Durability of Treatment on Mood at the 6-month Follow Up | Mood will be assessed with the PHQ-9, GAD-7, and POMS-SF | 1 time: 6 months | |
Other | Durability of Treatment on Sleepiness and Sleep Quality at the 6-month Follow Up | Sleepiness and Sleep Quality will be assessed with the ESS and PSQI | 1 time: 6 months | |
Primary | Change in Psychophysical Olfactory Function from Baseline to 4 and 12 Weeks | Sniffin' Sticks (Bughardt Messtechnik, Wedel Germany) will be used to determine odor threshold (T), odor discrimination (D), and odor identification (I), each on 16-point scales, and summed for a total TDI score. Higher scores indicate better function. | 2 times: 4 weeks, 12 weeks | |
Primary | Change in Perceived Intensity of Odorants from Baseline to 4 and 12 Weeks | Perceived intensity on 100-mm visual analog scales with anchor points: 0="imperceptible" to 100="extremely intense" will be rated for suprathreshold concentrations of PEA, vanilla, eugenol, and eucalyptus. | 2 times: 4 weeks, 12 weeks | |
Primary | Change in Perceived Hedonics of Odorants from Baseline to 4 and 12 Weeks | Perceived hedonics on 100-mm visual analog scales with anchor points: 0="extremely unpleasant" to 100="extremely pleasant". | 2 times: 4 weeks, 12 weeks | |
Primary | Change in Olfactory-related Quality of Life from Baseline to 4 and 12 Weeks | The Modified Questionnaire of Olfactory Disorders-Negative Statements (QOD-NS) consists of 17 negative statements (rated on a scale from 0 to 3; total score ranging from 0 to 51), with lower scores indicating better olfactory-related quality of life. | 2 times: 4 weeks, 12 weeks | |
Primary | Change in Impact of Olfactory Loss from Baseline to 4 and 12 Weeks | The Impact of Olfactory Loss Visual Analog Scale (IOL-VAS) consists of 9 separate items assessing the impact of olfactory loss upon mood, food enjoyment, social interactions, safety, hygiene, sex, cooking, appetite, and weight changes, rated from 0 (no impact) to 10 (biggest impact possible). | 2 times: 4 weeks, 12 weeks | |
Secondary | Change in Long COVID Symptoms from Baseline to 4 and 12 Weeks | 53 long COVID symptoms (scored from 0-53 reflecting the number of different symptoms experienced) and the impact of those symptoms (scored from 0=no impact to 10=maximal impact) will be obtained. | 2 times: 4 weeks, 12 weeks | |
Secondary | Change in Sustained Attention from Baseline to 4 and 12 Weeks | The Sustained Attention to Response Task (SART) is a computer-based go/no-go task that requires participants to withhold behavioral response to a single, infrequent target (often the digit 3) presented amongst a background of frequent non-targets (0-2, 4-9). | 2 times: 4 weeks, 12 weeks | |
Secondary | Change in Cognitive Function from Baseline to 4 and 12 Weeks | The NIH Toolbox Cognitive Battery is a widely used assessment for detecting cognitive impairment. This test assesses short-term memory, executable performance, attention, and focus. | 2 times: 4 weeks, 12 weeks | |
Secondary | Change in Mood State from Baseline to 4 and 12 Weeks | The Profile of Mood States Short Form (POMS-SF) is a psychological rating scale used to assess transient, distinct mood states across six different dimensions including Tension or Anxiety, Anger or Hostility, Vigor or Activity, Fatigue or Inertia, Depression or Dejection, and Confusion or Bewilderment. | 2 times: 4 weeks, 12 weeks | |
Secondary | Change in Sleep Quality from Baseline to 4 and 12 Weeks | The Pittsburgh Sleep Quality Index (PSQI) is a self-report questionnaire that assesses sleep quality over a 1-month time interval. The measure consists of 19 individual items, creating 7 components that produce one global score. Scores greater than 5 are indicative of a sleep disturbance. | 2 times: 4 weeks, 12 weeks | |
Secondary | Change in Excessive Daytime Sleepiness from Baseline to 4 and 12 Weeks | The Epworth Sleepiness Scale (ESS) is a measure intended to assess daytime sleepiness. Items consist of 8 different activities which are rated according to how likely it would be to doze off or fall asleep if engaged in that activity. A score of 10 or more is indicative excessive daytime sleepiness. | 2 times: 4 weeks, 12 weeks | |
Secondary | Change in Symptoms of Depression from Baseline to 4 and 12 Weeks | The Patient Health Questionnaire-9 (PHQ-9) is a self-administered 9-item questionnaire to screen for the presence and severity of depression. Items are rated on a 3pt scale ranging from 0="Not at all" to 3="Nearly every day". Total score ranges from 0-27 and is used to classify depression severity: 0-4=None/Minimal; 5-9=Mild; 10-14=Moderate; 15-19=Moderately Severe; 20-27=Severe. | 2 times: 4 weeks, 12 weeks | |
Secondary | Change in Symptoms of Anxiety from Baseline to 4 and 12 Weeks | The Generalized Anxiety Disorder-7 (GAD-7) is a 7-item questionnaire to screen for presence and severity of anxiety disorder. Items are rated on a 3pt scale ranging from 0="Not at all" to 3="Nearly every day". Total score ranges from 0 to 21 and is used to classify anxiety severity: 0-4 (minimal anxiety), 5-9 (mild anxiety), 10-14 (moderate anxiety), 15-21 (severe anxiety). | 2 times: 4 weeks, 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05926505 -
Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome
|
Phase 2/Phase 3 | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Completed |
NCT05552612 -
Health-related Quality of Life and Long COVID
|
||
Completed |
NCT05531019 -
COVID-19 Sequelae: Treatment and Monitoring. A Dietary Supplement Based on Sea Urchin Eggs With Echinochroma A
|
N/A | |
Not yet recruiting |
NCT04949386 -
Safety, Tolerability and Efficacy of S-1226 in Post-COVID-19 Subjects With Persistent Respiratory Symptoms.
|
Phase 2 | |
Recruiting |
NCT06118112 -
Living With Long COVID: LONGCOVID-EXPERIENCE
|
||
Completed |
NCT05185674 -
Sociodemographic, Clinical, Quality of Life and Health Care Conditions in COVID-19 Survivors.
|
||
Active, not recruiting |
NCT05965739 -
RECOVER-NEURO: Platform Protocol, Appendix_A to Measure the Effects of BrainHQ, PASC CoRE and tDCS Interventions on Long COVID Symptoms
|
N/A | |
Active, not recruiting |
NCT05965752 -
RECOVER-NEURO: Platform Protocol to Measure the Effects of Cognitive Dysfunction Interventions on Long COVID Symptoms
|
N/A | |
Completed |
NCT05812209 -
Stellate Ganglion Block to Treat Long COVID 19 Case Series
|
||
Recruiting |
NCT05606211 -
Pain in Long COVID-19: The Role of Sleep
|
||
Active, not recruiting |
NCT05713266 -
Using Data From a Multisensor Rapid Health Assessment Device to Predict Decompensation in Long COVID (AIDI)
|
||
Completed |
NCT05601180 -
Evaluation of the Efficacy of Respicure® (Resveratrol / Quercetin) in the Management of Respiratory Conditions Including Asthma,COPD and Long COVID.
|
N/A | |
Completed |
NCT05679505 -
Vagus Nerve Stimulation for Post-COVID Syndrome
|
N/A | |
Not yet recruiting |
NCT06045338 -
Mind Body Intervention for Long COVID
|
N/A | |
Recruiting |
NCT06091358 -
Inspiratory Muscle Training in People With Long COVID-19- A Pilot Investigation.
|
N/A | |
Recruiting |
NCT05566392 -
Longterm Influence of Pediatric Long COVID Syndrome
|
||
Recruiting |
NCT05572346 -
Digital App for Telerehabilitation in Respiratory Diseases
|
||
Recruiting |
NCT06316843 -
Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2
|
Phase 2 | |
Completed |
NCT06108297 -
Lithium Long COVID Dose-finding Study
|
Phase 1 |